Lear Rides on Product Mix Improvement, Margin Woes Linger

AXL MGA LEA FOXF

We issued an updated research report on Lear Corporation (LEA - Free Report) on Jul 12.

The company is a leading supplier of automotive seating and electrical systems (E-Systems), catering to several major automakers in the world. Both Seating and E-Systems segments offer huge growth opportunities. The rising mix of high-content crossover, luxury vehicles and sports utility vehicles (SUVs) is likely to drive the demand for the Seating segment. On the other hand, rising consumer demand for vehicle content along with growing electrification and connectivity requirements are propping up demand for the E-Systems segment.

Also, Southfield, MI-based Lear plans to launch many programs in fiscal 2018, with added content and opportunities for a profitable product-mix improvement. With its unique product capabilities in Seating and E-Systems, along with the continued convergence of the two segments, the company is extremely well positioned for growth in the future.

However, higher investments, to support backlog, significant program changeovers, accelerated new business activities and higher commodity costs — mainly on accounts of steel and copper, are straining the company’s margins.

In the past year, Lear’s stock has surged 26.9%, outperforming 9.9% increase recorded by the industry it belongs to.

Lear currently has a Zacks Rank #3 (Hold).

A few better-ranked stocks in the auto space are American Axle & Manufacturing Holdings, Inc. (AXL - Free Report) , Magna International Inc. (MGA - Free Report) and Fox Factory Holding Corp. (FOXF - Free Report) , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

American Axle & Manufacturing has an expected long-term growth rate of 8.1%. Over the past three months, shares of the company have inched up 0.2%.

Magna has an expected long-term growth rate of 8.5%. Over the past year, shares of the company have gained 24.7%.

Fox Factory has an expected long-term growth rate of 12.5%. Shares of the company have risen 42% over the past year.

5 Medical Stocks to Buy Now

Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.

New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.

Click here to see the 5 stocks >>

Zacks Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.

This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.

Free: See Our Top Stock and 4 Runners Up >>